ATOS Atossa Therapeutics

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Details of the company's participation are as follows:

  • Cantor Fitzgerald Global Healthcare Conference 2023
  • Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
  • Date and Time: Thursday, September 28th at 9:10 A.M. ET
  • Location: New York, NY

Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at . The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit .

Contact:

Eric Van Zanten

VP, Investor and Public Relations

610-529-6219



EN
18/09/2023

Underlying

ATOSAtossa Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atossa Therapeutics

 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 K...

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 24...

May 15, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces First Quarter 2024 Financial Results and...

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. ...

May 13, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Support of New Breast Cancer Screening G...

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The updated guidelines recommend women undergo bi...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Expanded Research Agreement with Weill C...

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology wit...

April 29, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clini...

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast c...

April 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch